Andreas Wollenberg
Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
Werfel T, Traidl-Hoffmann C, Schmid-Grendelmeier P, Lauener R, Bieber T, Wollenberg A, Simon H, Knol E, Hötzenecker W, Guttman-Yassky E, Gilles S, Eyerich K, Biedermann T, Allam J, Akdis C. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138:336-49.
01.08.2016Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
01.08.2016J Allergy Clin Immunol 2016; 138:336-49
Werfel Thomas, Traidl-Hoffmann Claudia, Schmid-Grendelmeier Peter, Lauener Roger, Bieber Thomas, Wollenberg Andreas, Simon Hans-Uwe, Knol Edward, Hötzenecker Wolfram, Guttman-Yassky Emma, Gilles Stefanie, Eyerich Kilian, Biedermann Tilo, Allam Jean-Pierre, Akdis Cezmi A
IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease
Friedrich M, Tillack C, Wollenberg A, Schauber J, Brand S. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. Inflamm Bowel Dis 2014; 20:1891-901.
01.11.2014IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease
01.11.2014Inflamm Bowel Dis 2014; 20:1891-901
Friedrich Matthias, Tillack Cornelia, Wollenberg Andreas, Schauber Jürgen, Brand Stephan
Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
Tillack C, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Maier H, Wetzke M, Ehmann L, Friedrich M, Laubender R, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Brand S. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2013; 63:567-77.
06.03.2013Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
06.03.2013Gut 2013; 63:567-77
Tillack Cornelia, Koburger Maria, Wagner Johanna, Glas Jürgen, Diegelmann Julia, Koglin Sarah, Dombrowski Yvonne, Schauber Jürgen, Wollenberg Andreas, Maier Harald, Wetzke Martin, Ehmann Laura Maximiliane, Friedrich Matthias, Laubender Rüdiger P, Papay Pavol, Vogelsang Harald, Stallhofer Johannes, Beigel Florian, Bedynek Andrea, Brand Stephan
Malignant melanoma during ustekinumab therapy of Crohn's disease
Ehmann L, Tillack-Schreiber C, Brand S, Wollenberg A. Malignant melanoma during ustekinumab therapy of Crohn's disease. Inflamm Bowel Dis 2011; 18:E199-200.
10.10.2011Malignant melanoma during ustekinumab therapy of Crohn's disease
10.10.2011Inflamm Bowel Dis 2011; 18:E199-200
Ehmann Laura M, Tillack-Schreiber Cornelia, Brand Stephan, Wollenberg Andreas